FEATURED

The Law That Rewired Drug Manufacturing

Start with the law, not the stock.

On December 18, 2025, the BIOSECURE Act was signed into the National Defense Authorization Act for Fiscal Year 2026. The law restricts U.S. government agencies from procuring biotechnology equipment or services from entities designated as “biotechnology companies of concern” — a category that the legislation was built to eventually capture WuXi AppTec and WuXi Biologics within. Then on June 8, 2026, the Department of Defense added WuXi AppTec to its Section 1260H list of Chinese military companies, triggering the first step in the formal designation process. WuXi AppTec has filed a legal challenge and denies any military affiliation. WuXi Biologics is not currently on that list.

Here is what the enforcement clock actually looks like.

OMB must publish a formal list of biotechnology companies of concern by December 2026, then issue implementing guidance within 180 days, and the FAR Council has one year after that to revise federal acquisition rules. Prohibitions take effect 60 days after the FAR is updated. If the government uses all available time, active restrictions on WuXi AppTec would not land until mid-to-late 2028 at the earliest — with a five-year grandfather period for existing contracts extending to approximately 2033. That is the legal outer limit. Congressional pressure is pushing OMB to move faster.

The part that matters for investors: the market is not waiting for 2028. Companies that rely on Chinese CDMOs for any program touching federal contracts, grants, or loans are already moving. Technology transfer timelines for biologics manufacturing typically run 12 to 24 months. If you wait for the formal list, you are already behind.

A survey by the Biotechnology Innovation Organization found that 79% of U.S. biopharmaceutical companies have a product or contract with a Chinese CDMO. WuXi AppTec alone generated approximately 65% of its 2023 revenues from U.S. customers. The scramble to find alternative manufacturing capacity — across some of the most complex biological drugs ever made — is already underway.

This is not a small inconvenience. This is a structural rupture in how global drug manufacturing works.

The global pharmaceutical CDMO market reached approximately $210 billion in revenue in 2025, up from roughly $170 billion in 2022. Growth has been driven by three forces running simultaneously: outsourcing penetration now sits at roughly 40% of total pharmaceutical manufacturing, up from about 30% in 2018; the pipeline has shifted heavily toward biologics, which now account for roughly 45% of all drugs in clinical development; and the complexity of novel drug modalities keeps pushing companies toward external manufacturing partners who have the specialized infrastructure they do not. The biologics CDMO segment is growing at approximately 12 to 15% annually — nearly double the overall market growth rate — driven by monoclonal antibody manufacturing, antibody-drug conjugates, bispecific programs, and the ongoing buildout of cell and gene therapy capacity.

Layering a forced supply chain rerouting on top of already stretched capacity is the part most investors have not fully thought through.

Capacity crunches — especially in biologics and cell therapy — can create 12 to 18 month wait times. The BIOSECURE Act and broader supply chain resilience concerns are driving companies to diversify manufacturing across multiple geographies. This dual-sourcing trend effectively doubles CDMO demand for companies that previously relied on a single supplier. India’s CDMO sector, estimated at roughly $6.9 billion by 2030 according to Jefferies, is already seeing demand acceleration. Lonza is widely considered best positioned to capture share from WuXi AppTec in biologics and cell and gene therapy manufacturing. Samsung Biologics, with its expanding Songdo campus and growing antibody-drug conjugate capabilities, is another. A 2025 survey of 18 CDMO operations leads in the U.S. found that 72% expected more than a quarter of their incremental commercial manufacturing volume over 2026 to 2028 to come from reshoring contracts previously held by Chinese CDMOs.

Wall Street is paying attention to the CDMOs themselves. That part is already being priced in.

What is not being priced in is one level deeper.

The Picks and Shovels Nobody Is Talking About

Every new biologics factory being built to absorb displaced volume runs on the same fundamental infrastructure: single-use bioprocessing systems. These are the disposable bags, filtration assemblies, chromatography columns, tubing sets, and fluid management components that make up the inside of a modern bioreactor. They are the consumables that get replaced with every single manufacturing batch.

This is not a one-time purchase. It is a recurring revenue stream with no meaningful substitute.

The single-use bioreactor bags market alone is projected to rise from $2.57 billion in 2025 to $3.03 billion in 2026, an 18% compound annual growth rate. The broader single-use bioprocessing market was valued at approximately $37.94 billion in 2025 and is expected to reach roughly $115 billion by 2035. Every new CDMO facility built to replace Chinese capacity — every greenfield biologics plant in Europe, the U.S., India, or South Korea — requires a full complement of these disposable systems to operate.

The shift from stainless steel bioreactors to single-use systems is itself a structural transition happening independent of BIOSECURE. Disposable assemblies turn the bioreactor into a plug-and-play engine, compressing changeover times from weeks to hours and improving manufacturing efficiency in ways that stainless steel simply cannot match at the batch level. CDMOs are choosing single-use not because they have to, but because the unit economics are better. BIOSECURE is accelerating a buildout that was already inevitable.

Now think about who supplies those disposable systems to every one of these new facilities.

Sartorius. Cytiva (owned by Danaher). Thermo Fisher. Merck KGaA. And a mid-cap company called Repligen that most equity investors have never had a real conversation about.

The Company Three Layers Removed

Repligen Corporation sits at the third or fourth derivative of the BIOSECURE story.

The first derivative is the law itself.
The second derivative is the CDMOs gaining market share.
The third derivative is the bioprocessing equipment and consumables those CDMOs must buy to operate.
Repligen is the component and consumable supplier to the suppliers.

Repligen has built a strong position in single-use bioprocessing through filtration, chromatography, and process intensification technologies. It does not manufacture drugs. It manufactures the filtration, chromatography, process analytics, and fluid management components that go inside every batch of every biologic. Those components get used once and discarded. Every new CDMO facility that comes online to replace displaced capacity becomes a new recurring revenue customer for Repligen — for as long as that facility runs.

The numbers are already confirming the acceleration. Repligen reported Q1 2026 revenue of $194 million, representing 15% reported growth and 11% organic growth year over year. Adjusted earnings per share came in at $0.48, compared to $0.39 in Q1 2025 — a 23% increase and a beat of more than 26% against analyst consensus of $0.38. Adjusted gross margin expanded 180 basis points year over year to 55.5%, driven by volume leverage, pricing, and product mix. Following Q1 results, the company updated its full-year 2026 revenue guidance to $803 million to $833 million, reflecting 9% to 13% reported revenue growth, while raising adjusted EPS guidance to $1.97 to $2.05.

One data point inside that quarter worth pausing on: Asia-Pacific revenue surpassed 25% growth year over year, and China revenue nearly doubled — the strongest quarter in the country in over two years. What that shows is that Repligen sells to every geography because biologics manufacturing is expanding everywhere simultaneously. New capacity is being added in South Korea, India, Europe, and the U.S., all at once, and all of it runs on single-use components.

The part investors are still working through is that Repligen is not just a bioprocessing recovery story. It is a structural beneficiary of a geopolitical reorientation of pharmaceutical manufacturing that has a multi-year runway. Capacity constraints are expected to intensify as a greater number of complex products enter the market. Compounding those pressures is the upcoming patent cliff for major biologics, which will unleash a significant wave of demand for biosimilar manufacturing. The biosimilar wave — driven by patent expirations on major drugs including Keytruda in 2028 and Opdivo in 2028 — is creating additional demand for CDMO biologics manufacturing capacity. More CDMOs running more batches. More Repligen consumables consumed per batch. Every year.

Analyst projections point to approximately $1.1 billion in Repligen revenue by 2029. The stock is not cheap on traditional metrics, but the earnings leverage is real. Each new CDMO facility that comes online creates recurring consumable demand that compounds with every batch run, indefinitely.

What the Market Is Missing

The coverage of BIOSECURE is treating this as a China risk story, not a demand acceleration story for Western bioprocessing infrastructure. Bloomberg is focused on the CDMOs themselves. The second-order beneficiary of those companies growing is the consumables they must buy to operate. That link is not being made clearly.

The assumption that is wrong: that BIOSECURE will disrupt the biopharma industry. The reality is that BIOSECURE will accelerate a capacity buildout that was already underway. The U.S. and European CDMO markets are experiencing their largest capacity expansion cycle in two decades. That buildout has a single-use consumables requirement that compounds annually with every new bioreactor that spins up.

One more thing worth watching: the dual-sourcing trend. The BIOSECURE Act and broader supply chain resilience concerns are pushing companies to diversify manufacturing across multiple geographies. That trend effectively doubles CDMO demand for companies that previously relied on a single supplier. More facilities running more batches means more consumable replacement cycles. Repligen sits at the intersection of all of it.

The biosimilar wave, the BIOSECURE Act, the shift from stainless to single-use, the CDMO capacity expansion in Western markets — these are not four separate stories. They are one story converging on the same infrastructure layer. Most of the market is watching the headline names. The more interesting angle is the company selling consumables to every single one of them.

The patent cliff arrives in 2028. The BIOSECURE enforcement clock is running, with OMB’s formal list due by December 2026 and full prohibitions expected no earlier than late 2028. The new CDMO facilities being built now will run on single-use systems for the next decade. The revenue from those facilities starts recurring the moment the first batch runs.

That clock is already running.